Periodontal disease initiation and progression occurs as a consequence of the host immune inflammatory response to oral pathogens. The production of inflammatory cytokines is a highly regulated process involving transcriptional and posttranscriptional mechanisms. At the posttranscriptional level, the presence of adenosine/uridine-rich elements (AREs) in the 3' untranslated region of many cytokine genes, including IL-6, TNF-a, and COX-2, targets the mRNA for rapid degradation. As a consequence, cytokine production is repressed. Tristetraprolin (TTP) is a zinc finger protein that binds to the ARE of cytokine mRNAs and enhances degradation of the mRNA. TTP is phosphorylated by the p38-MK2 pathway and may serve as a general mechanism of cytokine mRNA regulation. We have recently shown that LPS-induced IL-6 mRNA stability expression requires p38 signaling. Preliminary data for this proposal indicates that TTP transfected cells inhibit LPS-induced IL-6 expression. Based upon these data, we hypothesize that the mRNA decay enhancing properties of TTP may be exploited for potential anti-inflammatory purposes. In this proposal, the ability of TTP over-expression to decrease inflammation will be determined in vitro using gene targeted strategies in macrophages, and in vivo using experimental periodontitis models.
The specific aims are 1) to clarify the role of TTP on IL-6, TNF, and COX-2 mRNA expression and stability in vitro and 2) determine the impact of TTP in inflammatory and periodontal pathogen- initiated bone destruction in vivo using TTP-/- mice. These studies will establish the role of LPS-induced cytokine mRNA stability in inflammatory bone loss through selective mRNA decay targeting with TTP. Upon the accomplishment of these aims, subsequent studies will address the potential of TTP as a therapeutic strategy to control periodontal bone loss in small animal models. Periodontal disease initiation and progression occurs as a consequence of the host immune inflammatory response to oral pathogens. These studies will establish the role of host immune proteins termed cytokines and the regulation of cytokines at the level of mRNA stability in inflammatory bone loss through selective mRNA decay targeting with a protein that regulates cytokine mRNA stability. Progress in understanding the role of posttranscriptional cytokine regulation in periodontal inflammation and bone loss may yield new possibilities for treatment of periodontal diseases and other chronic inflammatory diseases. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21DE017966-01A1
Application #
7314281
Study Section
Oral, Dental and Craniofacial Sciences Study Section (ODCS)
Program Officer
Lumelsky, Nadya L
Project Start
2007-07-01
Project End
2008-02-29
Budget Start
2007-07-01
Budget End
2008-02-29
Support Year
1
Fiscal Year
2007
Total Cost
$85,500
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Dentistry
Type
Schools of Dentistry
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Zhao, Wenpu; Liu, Min; D'Silva, Nisha J et al. (2011) Tristetraprolin regulates interleukin-6 expression through p38 MAPK-dependent affinity changes with mRNA 3' untranslated region. J Interferon Cytokine Res 31:629-37
Van Tubergen, Elizabeth; Vander Broek, Robert; Lee, Julia et al. (2011) Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma. Cancer 117:2677-89
Li, Qiyan; Yu, Hong; Zinna, Robert et al. (2011) Silencing mitogen-activated protein kinase-activated protein kinase-2 arrests inflammatory bone loss. J Pharmacol Exp Ther 336:633-42
Sartori, R; Li, F; Kirkwood, K L (2009) MAP kinase phosphatase-1 protects against inflammatory bone loss. J Dent Res 88:1125-30
Kirkwood, Keith L; Rossa Jr, Carlos (2009) The potential of p38 MAPK inhibitors to modulate periodontal infections. Curr Drug Metab 10:55-67
Patil, Chetan S; Liu, Min; Zhao, Wenpu et al. (2008) Targeting mRNA stability arrests inflammatory bone loss. Mol Ther 16:1657-64